Company: TELO
Filing Date: 2025-11-10
Form Type: 10-Q
Source: 0001493152-25-021496
Chunk: 1

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-10
Form: 10-Q
Item: Item 1
Chunk 1
---
ited)

    Three Months Ended September,  
    Nine Months Ended September 30, 

    2025  
    2024  
    2025  
    2024 
  
    Revenues 
    $-  
    $-  
    $-  
    $- 
  
    Operating costs: 

    General and administrative expenses 
     386,951  
     5,378,744  
     7,264,808  
     6,999,981 
  
    Related party travel costs 
     -  
     -  
     -  
     370,500 
  
    Research and development expenses 
     759,525  
     627,434  
     1,139,360  
     1,966,258 
  
    Total operating costs 
     1,146,476  
     6,006,178  
     8,404,168  
     9,336,739 

    Interest income 
     44,182  
     15,445  
     53,544  
     40,939 
  
    Interest expense 
     -  
     -  
     (1,388) 
     (4,338,543)
  
    Net loss 
    $(1,102,294) 
    $(5,990,733) 
    $(8,352,012) 
    $(13,634,343)
  
    Basic and diluted loss per share 
    $(0.03) 
    $(0.20) 
    $(0.27) 
    $(0.46)
  
    Basic and diluted weighted average common stock shares outstanding 
     32,398,906  
     29,609,814  
     31,039,964  
     29,498,703 

See
notes to condensed unaudited financial statements

4

TELOMIR
PHARMACEUTICALS, INC.

CONDENSED
STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

FOR
THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024

(Unaudited)

    Common Stock  
    Additional
                                                                                Paid-In  
    Accumulated  
    Total Stockholders’ 

    Shares